Investigational drug · Phase 2
YL202 should be intravenously infused
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for NSCLC, Breast Cancer, HNSCC.
Phase 2Last checked: Nov 20, 2026Latest source record: Oct 14, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
2
Any phase or sponsor naming "YL202 should be intravenously infused"
First trial start
2023
Dec 15, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "YL202 should be intravenously infused", any sponsor or status.
Conditions studied
As listed on its trial records.
- NSCLC
- Breast Cancer
- HNSCC
- Locally Advanced or Metastatic Solid Tumors
- Locally Advanced or Metastatic Breast Cancer
Approved drugs for the same conditions: Breast cancer · Non-small cell lung cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "YL202 should be intravenously infused" as an intervention, largest first.
MediLink Therapeutics (Suzhou) Co., Ltd.Industry
NCT06107686 · 200 participants (planned) · Start Dec 15, 2023 · Primary completion Nov 2026
Drug: YL202 should be intravenously infused · For: NSCLC; Breast Cancer; HNSCC and 1 more
Sites: Hefei, China; Beijing, China; Chongqing, China · 82 sites in all
- A Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of YL202 in Patients With BCRecruiting
MediLink Therapeutics (Suzhou) Co., Ltd.Industry
NCT06439771 · 180 participants (planned) · Start Apr 23, 2024 · Primary completion Jul 30, 2027
Drug: YL202 should be intravenously infused · For: Locally Advanced or Metastatic Breast Cancer
Sites: Shanghai, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for NSCLC
- IvonescimabAK112, SMT112Phase 349 trials
Akeso · Non-Small Cell Lung Cancer, Advanced Malignant Tumors, Advanced Solid Tumors
- IfebemtinibIN10018, BI853520Phase 311 trials
InxMed (Shanghai) Co., Ltd. · Solid Tumor, NSCLC, Solid Tumor Cancer
- JAB-21822Glecirasib Citrate, KRAS G12C inhibitorPhase 310 trials
Allist Pharmaceuticals, Inc. · Non-small Cell Lung Cancer, KRAS P.G12C, Solid Tumor
- FurmonertinibPhase 38 trials
Allist Pharmaceuticals, Inc. · Non-Small Cell Lung Cancer, NSCLC, NSCLC Patients With Brain Metastasis
- PetosemtamabMCLA-158, GEN1158Phase 35 trials
Genmab · Head and Neck Squamous Cell Carcinoma, Colorectal Cancer, Advanced/Metastatic Solid Tumors
- FirmonertinibAST2818Phase 34 trials
Allist Pharmaceuticals, Inc. · Non-Small-Cell Lung Cancer, Metastatic Non-Small-Cell Lung Cancer, Advanced Non-Small-Cell Lung Cancer
- zoldonrasibPhase 34 trials
Revolution Medicines, Inc. · Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC
- EIK1001Phase 33 trials
Eikon Therapeutics · Advanced Melanoma, NSCLC, Non Small Cell Lung Cancer (Squamous or Non Squamous)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.